Articles By Rob Wright, Chief Editor 2011-2021

From Aha Moment To $10 Billion Biopharma
In 2012 Neil Kumar, Ph.D. read an article in Nature Biotechnology and was so inspired by the paper’s theories on drug discovery and development, that he eventually decided to quit his job and start his own biopharma called BridgeBio.  Continue Reading..
  • Got Your Zoom On?

    The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.

  • How An Industry Outsider Became A Biopharma CEO

    John Fowler had never worked in biopharma before. That didn’t stop his best friend — a scientist — from asking Fowler to lead the biotech startup he had been working on. It was a risk to both the company’s future — and their friendship.

  • How Has The Pandemic Impacted You — And Your People?

    Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts. 

  • The Making Of A CFO — A Conversation With J&J's Joseph Wolk

    Joe Wolk’s father spent 40 years working at the nearby J&J manufacturing facility. Now, Joe has reached the top of the organization as CFO. His path getting there, though, didn’t start in pharma.

  • The Streak — Is Over

    Our previous 16 regular issues of LSL (excluding the annual outlook issue) featured a biopharmaceutical company CEO on the cover. But our cover features aren’t limited to the CEO, as this month’s issue shows with our feature on J&J’s CFO Joe Wolk.

  • Is Biopharma's Reputation Back?

    While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.

  • Enanta Pharmaceuticals: From Failure To Formidable

    While working at a VC firm, Jay Luly, Ph.D., was tasked with assessing if Enanta Pharmaceuticals could be turned around, or if it should be shut down. Today the company is probably one of the most productive Big Pharma R&D engines you’ve never heard of — until now.

  • I Just Love A Good Turnaround Success Story

    IBM and GE are some famous business-focused turnaround stories, but this month we;’ve got a memorable one from the biopharma industry.

  • When A Pandemic Provides You Lemons

    Just as COVID changed our personal lives, it forced us to make changes to Life Science Leader, too. Ultimately, it is the reader who benefits from these changes, because we’re bringing you more of the content you want in more ways.

Rob Wright author page

Rob Wright

Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL